Table 1.
Patient summary characteristics grouped by type and stratified by outcome.
| No Remission | Remission | Missing | |
|---|---|---|---|
| n | 451 | 338 | 105 |
| Process | |||
| ICBT start week of year | 25.8 (16.1) | 24.1 (15.6) | 26 |
| MADRS-S time of day | 15:06:08 (5:10:04) | 16:01:15 (4:71:03) | 29 |
| EQ5D time to complete | 141.4 (308.2) | 133.96 (362.1) | 31 |
| Genetic | |||
| PRS-IQ (p ≤ 0.00001) | 0.05 (0.99) | −0.01 (1.04) | 0 |
| PRS-IQ (p ≤ 0.001) | −0.07 (0.97) | 0.08 (0.99) | 0 |
| PRS-IQ (p ≤ 0.05) | 0.00 (1.00) | 0.10 (0.96) | 0 |
| PRS-MDD (p ≤ 0.00001) | 0.02 (0.98) | −0.06 (1.03) | 0 |
| PRS-MDD (p ≤ 0.05) | −0.04 (0.88) | −0.11 (0.88) | 0 |
| PRS-ASD (p ≤ 0.00001) | −0.00 (0.97) | 0.03 (1.03) | 0 |
| PRS-ASD (p ≤ 0.001) | −0.00 (0.97) | 0.02 (1.02) | 0 |
| PRS-ADHD (p ≤ 0.00001) | −0.08 (1.00) | 0.04 (0.98) | 0 |
| PRS-ADHD (p ≤ 0.001) | −0.04 (0.97) | −0.09 (1.00) | 0 |
| PRS-BP (p ≤ 0.00001) | −0.07 (0.99) | 0.06 (1.04) | 0 |
| PRS-EDU (p ≤ 0.001) | 0.02 (0.95) | 0.11 (0.99) | 0 |
| PRS-EDU (p ≤ 0.05) | 0.07 (0.99) | 0.08 (0.94) | 0 |
| PRS-Ancestry (p ≤ 0.001) | 0.01 (1.07) | −0.02 (0.93) | 0 |
| Demographic | |||
| Age | 39.0 (11.9) | 37.8 (11.7) | 0 |
| Education | 4.9 (1.2) | 5.2 (1.2) | 2 |
| Work experience | 311 (69) | 259 (77) | 2 |
| Clinical | |||
| Prior mild MDD | 57 (13) | 59 (18.0) | 35 |
| Prior moderate MDD | 96 (22) | 72 (22) | 35 |
| Previous depression episodes | 5.6 (7.9) | 4.1 (5.2) | 0 |
| MADRS-S screen | 26.4 (5.7) | 23.3 (6.0) | 0 |
| MADRS-S pre | 24.0 (5.8) | 19.85 (6.0) | 0 |
| MADRS pre | 21.8 (5.8) | 19.7 (5.6) | 47 |
| PHQ-9 pre | 16.6 (5.1) | 13.7 (5.1) | 29 |
| EQ5D pre | 0.6 (0.2) | 0.7 (0.2) | 5 |
| EQ5D extreme anx/dep | 186 (43) | 89 (27) | 31 |
| EQ5D moderate pain | 216 (50) | 118 (36) | 31 |
| LSAS screen | 45.0 (25.2) | 38.1 (24.3) | 88 |
| PDSS screen | 5.5 (5.6) | 5.0 (5.4) | 34 |
| AUDIT screen | 5.6 (4.9) | 4.8 (4.4) | 2 |
| AUDIT-C screen | 3.5 (2.1) | 3.2 (2.0) | 59 |
| CGI-S pre | 3.7 (0.7) | 3.6 (0.8) | 111 |
| GSE pre | 24.7 (4.9) | 26.1 (5.0) | 263 |
| Prior psy meds | 0.9 (1.2) | 0.6 (0.9) | 0 |
| Current psy meds | 1.3 (1.3) | 0.9 (1.2) | 0 |
| No prior psy med | 139 (32) | 144 (44) | 35 |
| Any current psy med | 235 (65) | 147 (51) | 157 |
| Variable sleep-wake pattern | 174 (51) | 109 (43) | 218 |
| Reduced sex drive | 181 (58) | 131 (56) | 272 |
| Retarded speech | 28 (8) | 26 (10) | 207 |
| Reduced facial expressions | 35 (10) | 33 (13) | 213 |
| Agitation | 39 (11) | 27 (11) | 208 |
| GAF pre | 61.1 (7.2) | 62.7 (7.3) | 214 |
Data are integer count (%) or decimal mean (SD). Total sample n = 894.
See Table S2 in the Appendix for a full description of variables.
ADHD attention-deficit hyperactivity disorder, ASD autism spectrum disorder, AUDIT Alcohol Use Disorders Identification Test, BD bipolar disorder, CGIS Clinical Global Impression Scale, EQ5D-3L EuroQoL’s quality of life five dimension scale with three level items, EuroQoL European Quality of Life group, GAF Global Assessment of Functioning, GSS General Self-efficacy Scale, GWS genome-wide significance, ICBT internet-delivered cognitive behaviour therapy, LSAS Liebowitz Social Anxiety Scale, MADRS-S Montgomery-Åsberg Depression Rating Scale-Self report, MDD major depressive disorder, PDSS Panic Disorder Severity Scale, PRS polygenic risk score, SNP single-nucleotide polymorphism.